Managing Partner, Harris Kaplan, published in BioSpace: Why KOL Enthusiasm Often Doesn’t Predict Commercial Success
- 6 days ago
- 1 min read
Key opinion leaders play a critical role in shaping early perceptions of new therapies. But strong KOL enthusiasm does not always translate into broad market adoption.
In his latest BioSpace opinion article, Why Key Opinion Leader Enthusiasm Often Doesn’t Predict Commercial Success, Litmys Managing Partner Harris Kaplan explores the disconnect between early expert advocacy and real-world uptake—and why relying too heavily on KOL sentiment can lead to overestimated forecasts and missed expectations.
The article highlights the importance of looking beyond enthusiasm to understand the practical, behavioral, and system-level factors that ultimately determine whether a product succeeds in the market.
